secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001171843-25-003207
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics reports Q1 net loss of $2.8M; cash burn down; clinical progress in iNKT platform
--------------------------------------------------------------------------------

- Net loss of $2.8M ($0.70/sh) vs $3.8M ($1.10/sh) YoY; cash used in ops down to $1.3M from $2.5M.
- Cash balance of $3.2M at March 31, 2025; company pursuing near-term capital transactions to bolster liquidity.
- Phase 2 gastric trial (NCT06251973) enrolling; new data shows agenT-797 activity in PD-1-resistant gastroesophageal cancers.
- Complete remission in metastatic testicular cancer after single agenT-797 infusion without lymphodepletion or toxicity.
- Selected for probable NIAID funding for GvHD program; strategic discussions underway across oncology and immunology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184325003207/0001171843-25-003207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184325003207/f8k_051525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer